title: Cetuximab or bevacizumab in metastatic colorectal cancer?
authors.affiliation: Department of Medicine, The Royal Marsden NHS Foundation Trust Hospital, Sutton, Surrey, SM2 5PT, UK.
authors.forename: Francesco
authors.initials: F
authors.lastname: Sclafani
authors.affiliation: Department of Medicine, The Royal Marsden NHS Foundation Trust Hospital, Sutton, Surrey, SM2 5PT, UK. Electronic address: david.cunningham@rmh.nhs.uk.
authors.forename: David
authors.initials: D
authors.lastname: Cunningham
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000068818:Cetuximab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin